Lipid Matrix Sustained Release Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering nucleic acids, such as gene therapy, face challenges in achieving efficient and sustained release due to issues like charge repulsion between nucleic acids and cellular membranes, enzymatic degradation, and immunogenic responses, leading to poor bioavailability and stability concerns with existing delivery systems.
Innovation Solution
A lipid-based matrix composition incorporating a biocompatible polymer, polyethylene glycol (PEG), and specific lipids like sterols and phospholipids, which allows for efficient loading and controlled release of nucleic acids, providing sustained delivery and minimizing immunogenic responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for gene delivery, then transfection efficiency is improved, but immunogenic response and safety concerns increase
Solution Approach 1:
The patent uses non-viral lipid-based delivery vectors that are transient and do not persist in the body like viral vectors. These synthetic lipid complexes provide the necessary transfection efficiency temporarily without triggering long-term immune responses, effectively replacing persistent viral vectors with transient synthetic alternatives.
Solution Approach 2:
The invention employs composite lipid formulations combining multiple lipid components (ionizable lipids, helper lipids, cholesterol) to achieve viral-level transfection efficiency while maintaining the biocompatibility and low immunogenicity of non-viral systems. This composite approach allows optimization of both efficiency and safety parameters.
2Ease of operation
If naked plasmid DNA is administered, then simplicity of delivery is maintained, but bioavailability and stability decrease due to enzymatic degradation
Solution Approach 1:
The patent introduces lipid complexes as intermediary carriers that protect plasmid DNA from enzymatic degradation in the bloodstream and cellular environment. These lipid carriers facilitate DNA delivery through biological barriers while maintaining the simplicity of plasmid-based genetics, effectively mediating between simple naked DNA and complex protected formulations.
Solution Approach 2:
The invention modifies the physical-chemical parameters of DNA delivery by forming lipid-DNA complexes with specific charge, size, and stability characteristics. This transforms naked plasmid DNA into protected complexes that resist degradation while maintaining ease of administration, optimizing both bioavailability and delivery simplicity.
3Reliability
If high doses of plasmid are administered to overcome low bioavailability, then pharmacological response is achieved, but delivery efficiency decreases
Solution Approach 1:
The lipid complexes serve as efficient intermediary carriers that dramatically improve the delivery efficiency of plasmid DNA. By protecting the DNA and facilitating cellular uptake, these carriers enable achievement of pharmacological responses at much lower doses, effectively resolving the contradiction between response reliability and delivery efficiency.
4Duration of action of moving object
If sustained release is achieved through matrix composition, then therapeutic duration is extended, but release control precision must be maintained
Solution Approach 1:
The patent utilizes ionizable lipids that undergo pH-dependent parameter changes to control nucleic acid release. The lipids remain condensed at acidic pH (protecting the cargo during circulation) and become uncondensed at physiological pH (enabling sustained release at the target site). This parameter change mechanism provides both extended duration and precise release control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The matrix composition enables efficient local delivery and sustained release of nucleic acids, overcoming bioavailability and stability issues, with at least 30% of the nucleic acid agent released at zero-order kinetics, ensuring prolonged therapeutic effects.
Implementation Method 1
The matrix composition enables efficient local delivery and sustained release of nucleic acids, overcoming bioavailability and stability issues, with at least 30% of the nucleic acid agent released at zero-order kinetics
Implementation Method 2
A lipid-based matrix composition incorporating a biocompatible polymer, polyethylene glycol (PEG), and specific lipids like sterols and phospholipids, which allows for efficient loading and controlled release of nucleic acids, providing sustained delivery and minimizing immunogenic responses
Implementation Method 3
Polynucleotides do not readily permeate the cellular membrane due to the charge repulsion between the negatively charged membrane and the high negative charge on the polynucleotide
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention provides compositions for extended release of a nucleic acid agent, a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the nucleic acid agent.